Literature DB >> 2286433

Efficacy of three doses of oral polio immunization beginning within the first four days of life.

A M Bhatawdekar1, N B Kumta, K H Dave, B A Bharucha.   

Abstract

A study was carried out to test the efficacy of oral polio immunization commencing in the newborn period. In Group A, 47 term newborn infants were given trivalent oral polio vaccine (TOPV) within the first four days, at one month and at two months. In Group B, 21 infants were given TOPV at 3, 4 and 5 months. The seroconversion rates for types 1, 2 and 3 were 87.2, 95.7 and 72.3%, respectively in Group A and 85.7, 95.2 and 66.7%, respectively in Group B after 3 doses of TOPV, the differences being insignificant. Oral polio immunization beginning in the newborn period was as effective as when commenced at 3 months of age. Before immunization, the number of babies with protective titers against polioviruses were significantly more in Group A as compared to Group B. Thus, the later onset of immunization schedule leaves more children susceptible to poliomyelitis during the first 3 months of life.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2286433

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  4 in total

1.  Seroconversion following killed polio vaccine in neonates.

Authors:  P K Jain; A K Dutta; S Nangia; S Khare; A Saili
Journal:  Indian J Pediatr       Date:  1997 Jul-Aug       Impact factor: 1.967

2.  Effect of passively transferred anti-poliovirus antibodies on seroconversion.

Authors:  S B Bavdekar; S Naik; S S Nadkarni; J R Kamat; J M Deshpande; L K Vaswani
Journal:  Indian J Pediatr       Date:  1999 Jan-Feb       Impact factor: 1.967

3.  Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.

Authors:  William K Pan; Jessica C Seidman; Asad Ali; Christel Hoest; Carl Mason; Dinesh Mondal; Stacey L Knobler; Pascal Bessong
Journal:  Vaccine       Date:  2018-11-12       Impact factor: 3.641

Review 4.  Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies.

Authors:  Amira H Bakir; Martin Skarzynski
Journal:  Front Public Health       Date:  2015-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.